Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting
Objective: To evaluate beta blocker persistence six months after beta-blocker initiation or dose titration in heart failure (HF) patients with COPD compared to those without COPD. Secondary objectives included comparison of beta-blocker dose achieved, changes in left ventricular ejection fraction (LVEF) and incidence of hospitalizations or emergency department (ED) visits during follow-up.
Methods: We conducted a matched, retrospective, cohort study including 86 patients with COPD plus concomitant HF (LVEF ≤40%) and 137 patients with HF alone. All patients were followed in an outpatient HF clinic. Eligible patients had a documented LVEF ≤40% and were initiated or titrated on a beta-blocker in the HF clinic. Patients were matched based on LVEF (categorized as ≤ 20% or 21-40%), gender, and age (> or ≤70 years). The primary outcome was beta blocker persistence at 6 months. Secondary outcomes were dose achieved, LVEF, and incidence of hospitalizations or ED visits.
Results: There were no differences between the COPD and non-COPD groups in beta-blocker persistence at six-month follow-up (94.2% vs. 93.4% respectively, adjusted p=0.842). The proportion of patients who achieved a daily metoprolol dose equivalent of at least 100 mg was similar between the groups (adjusted p=0.188). The percent of patients with at least one ED visit or hospitalization in the six-month post-titration period was substantial but similar between the groups (53.5% and 48.2% for COPD and non-COPD patients, respectively, adjusted p=0.169).
Conclusion: Our results support the use of beta-blockers in the population of heart failure patients with COPD and without reactive airway disease.
2. Heart Failure Society of America Writing Committee Co-Chaired by Adams, KF and Lindenfeld J. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:e1-e119. doi:10.1016/j.cardfail.2005.12.001
3. Brophy JM, Joseph L, Rouleau JL. Beta-Blockers in Congestive Heart Failure. A bayesian meta-analysis. Ann Intern Med. 2001;134:550-560.
4. The MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295-1337. doi:10.1001/jama.283.10.1295
5. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-2007. doi:10.1016/S0140-6736(99)04440-2
6. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet. 1999;353:9-13. doi:10.1016/S0140-6736(98)11181-11189
7. Sinha S, Goldstein M, Penrod J, Hochman T, Kamran M, Tenner C, Cohen G, Schwartz MD. Brief report: beta-blocker use among veterans with systolic heart failure. J Gen Intern Med. 2006;21:1306-1309. doi:10.1111/j.1525-1497.2006.00601.x
8. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest. 2003;123:222-243. doi:10.1378/chest.123.1.222
9. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation .2002;106:394-398. doi:10.1161/01.CIR.0000019582.39797.EF
10. Sirak, TE, Jelic S, LeJemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2004;44(3):497-502. doi:10.1016/j.jacc.2004.03.063
11. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49;171-180. doi:10.1016/j.jacc.2006.08.046
12. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818-824. doi :10.1378/chest.127.3.818
13. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med. 2005;98:493-497. doi:10.1093/qjmed/hci080
14. Shelton RJ, Rigby AS, Clelan JGF, Clark AL. Effect of a community heart failure clinic on uptake of beta-blockers by patients with obstructive airways disease and heart failure. Heart. 2006;92:331-336. doi:10.1136/hrt.2004.059758
15. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther. 1990;4:1145-1149. doi:10.1007/BF01856511
16. Mascarenhas J, Lourenco P, Lopes R, Bettencourt P. Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521-525. doi:10.1016/j.ahj.2007.10.040
17. Salpeter S, Ormiston t, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003566. doi:10.1002/14651858.CD003566.pub2
18. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21(12):1290-1295. doi:10.1016/S1053-2498(02)00459-X
19. GOLD Executive and Science Committees. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available at: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003 (accessed 19 February 2009).
20. Haley RJ, Licht JH: Metoprolol, atenolol, and propranolol: a comparison at equivalent doses in the treatment of hypertension. Curr Ther Res Clin Exp. 1984;36:993-1003.
21. van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrüugge W, König S, Griffiths M and Lahiri A. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol. 1999;83:643-649. doi:10.1016/S0002-9149(98)00960-6
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Author Self-Archiving Policy
Pharmacy Practice permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.